Active substance
Nizatidine
- SFDA 7
- US FDA 13
- Health Canada 1
- US price lines 2
- NHS prices 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FIXIT 150MG CAPSULE | 150 mg | Capsule, hard · Oral use | 14 Blister | SAR 26.20 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| FIXIT 150MG CAPSULE | 150 mg | Capsule, hard · Oral use | 28 Blister | SAR 52.40 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| FIXIT 300MG CAPSULE | 300 mg | Capsule, hard · Oral use | 14 Blister | SAR 52.40 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| AXID 150MG CAPS | 150 mg | Capsule · Oral use | 28 Blister | SAR 58.25 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| AXID 300MG CAPS | 300 mg | Capsule · Oral use | 14 Blister | SAR 58.25 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| FIXIT 75MG CAPSULE | 75 mg | Capsule, hard · Oral use | 14 Blister | SAR 19.30 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Withdrawn by MAH · Not Marketed |
| FIXIT 75MG CAPSULE | 75 mg | Capsule, hard · Oral use | 28 Blister | SAR 33.40 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ ASPIRATION PNEUMONIA PROPHYLAXIS; DYSPEPSIA; GASTROESOPHAGEAL REFLUX DISEASE (GERD); PEPTIC ULCER
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| AXID AR | 75MG | tablet · oral | HALEON US HOLDINGS | Over-the-counter | 9 May 1996 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | EPIC PHARMA LLC | Prescription | 5 Jul 2002 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | WATSON LABS | Prescription | 9 Jul 2002 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | DR REDDYS LABS LTD | Prescription | 15 Sep 2005 |
| AXID | 150MG; 300MG | capsule · oral | SMITHKLINE BEECHAM | Discontinued | 12 Apr 1988 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | PHARMOBEDIENT | Discontinued | 5 Jul 2002 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | ANI PHARMS | Discontinued | 8 Jul 2002 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | MYLAN PHARMS INC | Discontinued | 9 Jul 2002 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | ANI PHARMS | Discontinued | 12 Sep 2002 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | APOTEX INC | Discontinued | 23 Jan 2003 |
| AXID | 15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · oral | BRAINTREE | Discontinued | 25 May 2004 |
| NIZATIDINE | 15MG/ML | solution · oral | AMNEAL PHARMS | Discontinued | 18 Nov 2009 |
| NIZATIDINE | 150MG; 300MG | capsule · oral | GLENMARK PHARMS | Discontinued | 15 Jul 2011 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AXID | 00778338 | 150 MG | CAPSULE · ORAL | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NIZATIDINE 150 MG CAPSULE | $0.80421 | per EA | 23 Sep 2026 |
| US NADAC | NIZATIDINE 300 MG CAPSULE | $0.79878 | per EA | 17 Jun 2026 |
| NHS Drug Tariff | Nizatidine 150mg capsules | £76.41 | 30 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nizatidine 300mg capsules | £133.33 | 30 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 9 Apr 2019 AXID AR — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.